CNS Pharmaceuticals Shares Surge 330% Amid Strategic Shift

Written by Emily J. Thompson, Senior Investment Analyst

Source: stocktwits

Updated: 1 hour ago

0mins

CNSP+268.66%

Should l Buy CNSP?

Source: stocktwits

Financing Strategy: CNS Pharmaceuticals plans to utilize $22.5 million from a private placement, alongside existing cash, to identify and acquire new drug candidates in neurology and oncology, demonstrating the company's strong execution capability in a dynamic biotech environment.
Stock Performance: Shares of CNS Pharmaceuticals surged over 330% in early trading on Monday, marking the largest single-day gain since the 1-for-12 reverse stock split last July, reflecting strong investor confidence in the company's acquisition strategy.
Asset Acquisition Focus: The company aims to prioritize preclinical and clinical-stage assets with clear development paths and strong commercial potential while looking to out-license legacy programs like Berubicin and TPI-287 to optimize resource allocation.
Market Sentiment Shift: Retail sentiment for CNS Pharmaceuticals on Stocktwits shifted from neutral to 'extremely bullish' with extremely high message volumes, indicating strong investor interest in future growth potential, although some users anticipate a significant drop in stock price.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy CNSP?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on CNSP

Wall Street analysts forecast CNSP stock price to rise

1 Analyst Rating

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.311

Low

20.00

Averages

20.00

High

20.00

Current: 2.311

Low

20.00

Averages

20.00

High

20.00

UBS

Neutral

maintain

$63 -> $66

2026-01-08

Reason

UBS

Price Target

$63 -> $66

AI Analysis

2026-01-08

maintain

Neutral

Reason

UBS raised the firm's price target on Centerspace to $66 from $63 and keeps a Neutral rating on the shares. 2026 is expected to mark a pivotal REIT turnaround, with forecast total returns of 9%-11% driven by improving macro conditions, attractive valuations, easing supply pressures, and a more stable political backdrop, the analyst tells investors in a research note. The outlook points to a bifurcated year with defensiveness in the first half of 2026 and stronger catalysts in the second half, favoring Healthcare, Shopping Centers, and Coastal Apartments, UBS says.

Cantor Fitzgerald

Richard Anderson

Neutral

maintain

$62 -> $65

2026-01-05

Reason

Cantor Fitzgerald

Richard Anderson

Price Target

$62 -> $65

2026-01-05

maintain

Neutral

Reason

Cantor Fitzgerald analyst Richard Anderson raised the firm's price target on Centerspace to $65 from $62 and keeps a Neutral rating on the shares. U.S. equity REITs returned 2.9% in 2025, lagging the S&P 500, but 2026 may offer optimism with a potentially more supportive macro environment and an accelerating M&A theme, the analyst tells investors in a research note. Stable supply and demand fundamentals, balance sheet strength, and a well-covered, growing 4% dividend yield make the sector attractive despite past underperformance, Cantor adds.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CNSP

Unlock Now

About CNSP

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.